Blockchain Registration Transaction Record

Cybin Completes Phase 2 Enrollment for Anxiety Treatment CYB004

Cybin completes Phase 2 enrollment for CYB004, a deuterated DMT treatment for Generalized Anxiety Disorder. Topline data expected Q1 2026 for novel psychedelic therapy.

This development matters because Generalized Anxiety Disorder affects millions worldwide, with current treatments often proving ineffective for half of patients. The advancement of novel psychedelic-based therapies like CYB004 represents a potential paradigm shift in mental healthcare, offering hope for those who have exhausted conventional options. Successful development could lead to more accessible, effective, and convenient treatment options, potentially reducing the global burden of anxiety disorders and improving quality of life for countless individuals.